Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
VENUSREM

Venus Remedies Share Price

 

 

Venus Remedies live price: ₹1024. It opened at ₹1,022 vs previous close ₹1,023; intraday high/low: ₹1,069/₹1,020. The 50 & 200 DMA stand at ₹862.25/₹670.47.

Venus Remedies Performance

  • Today's Low
  • ₹1,020
  • Today's High
  • ₹1,069
  • 52 Week Low
  • ₹294
  • 52 Week High
  • ₹1,089
  • Open Price₹1,022
  • Previous Close₹1,023
  • Volume31,845
  • 50 DMA₹862.25
  • 100 DMA₹780.91
  • 200 DMA₹670.47

Venus Remedies Chart

Investment Returns

  • Over 1 Month + 17.94%
  • Over 3 Month + 41%
  • Over 6 Month + 125.5%
  • Over 1 Year + 202.42%

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 17.9
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 1,369
  • P/B Ratio
  • 2.2
  • Average True Range
  • 51.39
  • EPS
  • 57.09
  • Dividend Yield
  • 0
  • MACD Signal
  • 53.42
  • RSI
  • 65.48
  • MFI
  • 72.51

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹1,024.00
+ 1.15 (0.11%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹946.81
  • 50 Day
  • ₹862.25
  • 100 Day
  • ₹780.91
  • 200 Day
  • ₹670.47

Resistance and Support

1037.4 Pivot Speed
  • R3 1,130.10
  • R2 1,104.05
  • R1 1,063.45
  • S1 996.80
  • S2 970.75
  • S3 930.15

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 699.88 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 26% and 64% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 21% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 97 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-29 Quarterly Results & Others To consider other business matters.
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-07-08 Others Inter-alia, to consider 1. Notice of 36th Annual General Meeting. 2. Boards Report for Financial Year 2024-2025. 3. Other business matters.
2025-05-26 Audited Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
2.8%
44.4%
11.04%

Venus Remedies FAQs

Venus Remedies share price is ₹1,024 As on 21 April, 2026 | 17:28

The Market Cap of Venus Remedies is ₹1368.8 Cr As on 21 April, 2026 | 17:28

The P/E ratio of Venus Remedies is 17.9 As on 21 April, 2026 | 17:28

The PB ratio of Venus Remedies is 2.2 As on 21 April, 2026 | 17:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23